New hope for Hard-to-Treat breast cancer: targeted combo trial launches
NCT ID NCT07393321
First seen Feb 06, 2026 · Last updated May 14, 2026 · Updated 13 times
Summary
This phase 3 trial tests whether adding the experimental drug NTQ1062 to standard hormone therapy (fulvestrant) can slow or stop cancer growth in people with advanced HR+/HER2- breast cancer that has specific genetic changes (PIK3CA/AKT1/PTEN). About 210 adults whose cancer worsened after prior hormone therapy will receive either the combo or a placebo plus fulvestrant. The study aims to see if the new drug extends time without cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR POSITIVE/HER2 NEGATIVE ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.